Back to Search
Start Over
Glioblastoma-Derived Exosomes as Nanopharmaceutics for Improved Glioma Treatment.
- Source :
- Pharmaceutics; May2022, Vol. 14 Issue 5, p1002-1002, 20p
- Publication Year :
- 2022
-
Abstract
- The use of cancer-derived exosomes has been studied in several cancer types, but the cancer-targeting efficacy of glioma-derived exosomes has not been investigated in depth for malignant glioblastoma (GBM) cells. In this study, exosomes were derived from U87MG human glioblastoma cells, and selumetinib, a new anticancer drug, was loaded into the exosomes. We observed the tropism of GBM-derived exosomes in vitro and in vivo. We found that the tropism of GBM-derived exosomes is in contrast to the behavior of non-exosome-enveloped drugs and non-GBM-specific exosomes in vitro and in vivo in an animal GBM model. We found that the tropism exhibited by GBM-derived exosomes can be utilized to shuttle selumetinib, with no specific targeting moiety, to GBM tumor sites. Therefore, our findings indicated that GBM-derived exosomes loaded with selumetinib had a specific antitumor effect on U87MG cells and were non-toxic to normal brain cells. These exosomes offer improved therapeutic prospects for glioblastoma therapy. [ABSTRACT FROM AUTHOR]
- Subjects :
- EXOSOMES
GLIOMAS
GLIOBLASTOMA multiforme
ANTINEOPLASTIC agents
Subjects
Details
- Language :
- English
- ISSN :
- 19994923
- Volume :
- 14
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Pharmaceutics
- Publication Type :
- Academic Journal
- Accession number :
- 157245301
- Full Text :
- https://doi.org/10.3390/pharmaceutics14051002